Single Agents in Cancer Chemotherapy

  • Robert B. Livingston
  • Stephen K. Carter

Table of contents

  1. Front Matter
    Pages i-x
  2. Robert B. Livingston, Stephen K. Carter
    Pages 1-2
  3. Robert B. Livingston, Stephen K. Carter
    Pages 3-24
  4. Robert B. Livingston, Stephen K. Carter
    Pages 25-80
  5. Robert B. Livingston, Stephen K. Carter
    Pages 81-98
  6. Robert B. Livingston, Stephen K. Carter
    Pages 99-111
  7. Robert B. Livingston, Stephen K. Carter
    Pages 112-129
  8. Robert B. Livingston, Stephen K. Carter
    Pages 130-172
  9. Robert B. Livingston, Stephen K. Carter
    Pages 173-194
  10. Robert B. Livingston, Stephen K. Carter
    Pages 195-226
  11. Robert B. Livingston, Stephen K. Carter
    Pages 227-237
  12. Robert B. Livingston, Stephen K. Carter
    Pages 238-256
  13. Robert B. Livingston, Stephen K. Carter
    Pages 257-270
  14. Robert B. Livingston, Stephen K. Carter
    Pages 271-278
  15. Robert B. Livingston, Stephen K. Carter
    Pages 279-297
  16. Robert B. Livingston, Stephen K. Carter
    Pages 298-317
  17. Robert B. Livingston, Stephen K. Carter
    Pages 318-336
  18. Robert B. Livingston, Stephen K. Carter
    Pages 337-358
  19. Robert B. Livingston, Stephen K. Carter
    Pages 359-402
  20. Back Matter
    Pages 403-405

About this book

Introduction

The clinical trials program of anti-tumor drugs was started by the National Cancer Institute in 1955. In the past 15 years, this national network has collected a large body of data on all of the recognized anti-tumor drugs as well as upon new, experimentally promising agents. While the most important of these studies have been published, there has remained a wealth of data not generally available to the scientific community. Drs. Carter and Livingston have not only succeeded in organ~z~ng this large corpus, they have in addition analyzed and interpreted the clinical data in a way that will be highly useful for years to come. From a perusal of this volume it becomes apparent that some drugs are more active against certain tumors than had been realized; that the evidence for the activity of certain drugs against specific tumors is sometimes tenuous; surprisingly, that some highly active agents have never been tried against some of the fairly common tumors. Their monumental work has provided not only access to the hard data, it has also shown the need for research to fill in important gaps in our knowledge. The authors and the IFI/Plenum Press are to be congratulated for this useful and important work. C. Gordon Zubrod, M. D. Scientific Director for Chemotherapy National Cancer Institute National Institutes of Health Bethesda, Maryland v Acknowledgment The authors wish to thank Dr. C. Gordon Zubrod and Dr.

Keywords

cancer chemotherapy clinical trial research

Authors and affiliations

  • Robert B. Livingston
    • 1
  • Stephen K. Carter
    • 1
  1. 1.National Cancer InstituteBethesdaUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-1-4684-1378-6
  • Copyright Information Springer-Verlag US 1970
  • Publisher Name Springer, Boston, MA
  • eBook Packages Springer Book Archive
  • Print ISBN 978-1-4684-1380-9
  • Online ISBN 978-1-4684-1378-6
  • About this book